Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Study to Evaluate the Safety and Efficacy of AMG 655 or AMG 479 in Combination With Gemcitabine as First-Line Therapy for Metastatic Pancreatic Cancer

NCT00630552 is registered in ClinicalTrials.gov with NantCell, Inc. as lead sponsor.

NCT NCT00630552
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00630552 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Study to Evaluate the Safety and Efficacy of AMG 655 or AMG 479 in Combination With Gemcitabine as First-Line Therapy for Metastatic Pancreatic Cancer
Lead sponsor
NantCell, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
June 30, 2007
Completion date
April 30, 2012
Enrollment
138 (actual)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of the pancreas, metastatic pancreatic cancer, pancreatic cancer